VRTX

Vertex Pharmaceuticals Incorporated

Price

$444.28

return (12m)

p/e

28.35

p/bv

6.35

DIVIDEND YIELD

0.00%

VRTX price

Vertex Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment VRTX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals VRTX

Valuation

P/E

28.35

Sector -4.15

Industry -4.15

P/BV

6.35

Sector 2.06

Industry 2.06

P/Revenue (PSR)

10.07

Sector -4.16

Industry -4.16

EV/EBITDA

96.88

Sector -241.86

Industry -241.86

EV/EBIT

101.63

Sector -671.75

Industry -671.75

P/EBITDA

23.30

Sector -4.30

Industry -4.30

P/EBIT

24.30

Sector -4.35

Industry -4.35

P/Total Assets

4.64

Sector 1.46

Industry 1.46

P/Net Current Assets

26.69

Sector -12.67

Industry -12.67

P/Working Capital

15.67

Sector -12.58

Industry -12.58

EPS

17.08

Sector -2.19

Industry -2.19

BVPS

76.23

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

86.24%

Sector 36.44%

Industry 36.44%

EBITDA Margin

40.00%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

38.13%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

38.16%

Sector -38.78%

Industry -38.78%

Net Profit Margins

35.51%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.11

Sector 0.03

Industry 0.03

Profitability

ROE

22.41%

Sector -67.01%

Industry -67.01%

ROA

16.38%

Sector -66.28%

Industry -66.28%

ROIC

23.95%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.02

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-6.07

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

-6.36

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.37

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.73

Sector 0.42

Industry 0.42

Liabilities/Assets

0.27

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

10.03%

Sector -

Industry -

5Y Earnings CAGR

13.12%

Sector -

Industry -

FAIR VALUE OF Vertex Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$444.28

Fair Value

$171.16

Upside Return potential.

-61.48%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals VRTX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
VRTX Vertex Pharmaceuticals Incorporated	$444.28	-8.25%	0.00%	28.35	6.35	22.41%	35.51%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

VRTX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Average Investor10 user rating

4.0 (0 people)

States of America

37 years

Founded: 1989

1991

Time since IPO - 35 years

3.400

Employees

Vertex Pharmaceuticals Incorporated (States of America) is listed on the Nasdaq and has a market capitalization of $122.99 billion, with shareholders equity totaling $19.36 billion.

The company employs approximately 3.400 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Vertex Pharmaceuticals Incorporated reported $12.22 billion in revenue, generating net income of $4.34 billion.

Key financial metrics include a P/E ratio of 28.35, a price-to-book (P/B) ratio of 6.35, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker VRTX.

Market cap

$122.99 billion

Net worth

$19.36 billion

$19,361,900,000.00

Assets

$26.48 billion

$26,484,400,000.00

Total Shares Outstanding

254.00 million

254,000,000

Average Daily Trading Volume

$1.60 million

$1,599,506.18

Sector

Healthcare

Industry

Biotecnologia

VRTX

revenue by Business Segment Vertex Pharmaceuticals

VRTX revenue and profits

Financial Results VRTX

DRAG THE FRAME TO SEE MORE DATA

VRTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14